HSV sensitivity to antiviral drugs is highly dependent on viral multiplicity, suggesting isolates from treatment failures should be assayed in detail.
May necessitate multiplicity-adjusted HSV susceptibility assays in treatment failures; leaves open standardization of clinical testing protocols.
An immunoassay that enables one to assess both viral multiplicity and sensitivity to antiviral drugs, was used to determine the sensitivity of untreated patients' virus isolates. The upper border levels for judging clinical isolates sensitive to Ara-A, ACV, PFA or IDU were calculated from a total of 48 primary herpes simplex isolates. Although five isolates were considered less sensitive to one drug and one isolate to two drugs, all were sensitive at a lower virus multiplicity. Analysis of these isolates showed that no isolate was genetically resistant, but that multiplicity dependence of drugs was high with ACV and Ara-A, lower with PFA. In view of the multiplicity dependence of HSV sensitivity to different drugs, it is recommended that isolates from treatment failures or isolates considered resistant should be assayed in detail.
No takes yet. Share an insight, caveat, or question.
Harmenberg et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: